Clinical trial · Observational
On the Impact of Therapeutic Tumor Necrosis Factor-alpha Inhibition on Anogenital Human Papillomavirus Infection
NCT02376478CI-TRIAL-00016972completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
In this prospective, open, controlled, cross-sectional observational study patients with psoriasis or IBD, who received either anti-TNF-alpha inhibitors or alternates (purine-, folic acid analogues, phototherapy, fumaric ester, mesalazine) for their underlying disease were included. Anogenital HPV-induced lesions, mucosal HPV DNA and serological status of mucosal low-risk (HPV6) and high-risk HPV (HPV16, HPV18) were determined.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Inflammatory Bowel Diseases | — | UNRESOLVED | — |
| Psoriasis | — | UNRESOLVED | — |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Alternative/no medication | Drug | — | UNRESOLVED |
| Purine/folic acid analogues | Drug | — | UNRESOLVED |
| TNF-alpha inhibitors | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (4)
- label
- TNF-alpha inhibitors
- description
- TNF-alpha Inhibitors: patients with psoriasis or inflammatory bowel diseases under TNF-alpha inhibitor monotherapy
- interventionNames
- Drug: TNF-alpha inhibitors
- label
- Purine/folic acid analogues
- description
- Purine/folic acid analogues: patients with psoriasis or inflammatory bowel diseases receiving monotherapy with purine or folic acid analogues, such as azathioprin, 6-mercaptopurine, or methotrexate
- interventionNames
- Drug: Purine/folic acid analogues
- label
- Combination therapy
- description
- Combination therapy: patients with psoriasis or inflammatory bowel diseases receiving combination therapy with TNF-alpha blocker plus purine or folic acid analogues
- interventionNames
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: * Participants between 18-80 years of age with a history of psoriasis or inflammatory bowel diseases, namely Crohn's disease and ulcerative colitis, and * at least 6 month of continuous treatment regimen. Exclusion Criteria: * Pregnant or nursing patients and * patients with inherited immune disorders, human immunodeficiency virus infection, invasive malignancies or psychomotor retardation and * patients with psoriasis or inflammatory bowel diseases who had received high-dose corticosteroids during the past 6 months.
References
Publications (0)
Data not yet available
No reference posted for this study.